ChemGenex Pharmaceuticals Limited - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for ChemGenex Pharmaceuticals Limited. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

ChemGenex Pharmaceuticals Limited. The Group's principal activity is operating as an integrated biopharmaceutical development company, focusing on the discovery of new therapeutic targets and the development of drugs in the fields of cancer, metabolic syndrome (obesity and diabetes) and depression. Its product candidates include Omacetaxine, which is currently in phase 2/3 clinical trials for chronic myelogenous leukemia (CML); Quinamed, which is in phase 2 clinical development for prostate, breast and ovarian cancers; and CXS-299, which is in late pre-clinical development for the treatment of solid tumors refractory to chemotherapy. It also has a portfolio of anti-cancer, diabetes and obesity programs, several of which have been partnered with international pharmaceutical companies. Based in Geelong, Australia, the Group's operations are conducted in Australia and the United States of America.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report